Mebeverine Zentiva (Mebeverine)

Mebeverine is an antispasmodic that acts on smooth muscle of the gastrointestinal tract to alleviate functional bowel conditions.

• Irritable bowel syndrome: reduces abdominal pain, cramping and irregular bowel movements.
• Functional bowel disorders: improves stool consistency and decreases episodes of spasm.
• Chronic abdominal discomfort: alleviates persistent gastrointestinal discomfort associated with motility disturbances.

• Mebeverine directly relaxes gastrointestinal smooth muscle by inhibiting calcium influx into the muscle cells, which reduces spasm without exhibiting anticholinergic activity. This calcium channel modulation lowers the contractile tone of the gut wall, helping to normalize motility and relieve pain associated with functional gastrointestinal disorders.

Mebeverine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Dry mouth: reduced salivation.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Abdominal pain: mild discomfort in the stomach area.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or swelling.
• Severe skin eruption: Stevens‑Johnson‑like rash.
• Hepatic dysfunction: elevated liver enzymes.
• Significant hypotension: marked drop in blood pressure.
• Cardiac arrhythmia: irregular heart rhythm.
• Urinary retention: difficulty emptying the bladder.

Before initiating therapy, consider the following precautions.

• Renal or hepatic impairment: assess function and adjust use if necessary.
• Elderly patients: monitor for increased sensitivity to side effects.
• Known hypersensitivity: avoid if allergic to mebeverine or excipients.
• Concomitant cardiac disease: watch for rare cardiovascular effects.
• Use with caution when combined with other smooth‑muscle relaxants.
• Store at below 25°C: keep in the original pack, protect from moisture.

Mebeverine may interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase mebeverine plasma concentrations.
• Other potent smooth‑muscle relaxants: additive risk of excessive gastrointestinal relaxation.

Moderate Interactions (Monitor Closely)

• Antihistamines: may enhance anticholinergic‑like dryness.
• Antidepressants (tricyclics, SSRIs): monitor for overlapping gastrointestinal effects.
• Other gastrointestinal motility agents: adjust dosing to avoid over‑correction of motility.